- Market Capitalization, $K 123,999,080
- Shares Outstanding, K 2,623,764
- Annual Sales, $ 22,090 M
- Annual Income, $ 2,155 M
- 60-Month Beta 0.48
- Price/Sales 5.56
- Price/Cash Flow 14.57
- Price/Book 8.98
|Period||Period Low||Period High||Performance|
| || |
+3.30 (+7.57%)since 10/11/19
| || |
+2.11 (+4.71%)since 08/09/19
| || |
+5.91 (+14.43%)since 11/09/18
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
--Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA(R) (dapagliflozin) for the treatment of heart failure (HF). The data showed that...
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
--ROCKIES demonstrated a mean increase of 0.77g/dL averaged over weeks 28 to 52, compared to 0.68g/dL with epoetin alfa
AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing CALQUENCE(R) (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, in patients with...
Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target...
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
BMY vs. AZN: Which Stock Is the Better Value Option?
Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.
|Multifactor Low Volatility International Equity|
|Lattice Developed Markets Ex-US ETF|
|Intl High Divd Yld ETF Vanguard|
|Advisorshares Doubleline Value Equity ETF|
|Goldman Sachs Access Investment Grade Corp Bond|